Last reviewed · How we verify
NCT06632340
Effect of Tumor Base Size in Bladder Cancer
NA trial testing TUR-BT in Bladder Cancer in 130 participants. Completed in 1 January 2024.
30 September 2023
Quick facts
| Lead sponsor | Ankara Training and Research Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 130 |
| Start date | 1 March 2021 |
| Primary completion | 30 September 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- TUR-BT
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Ankara Training and Research Hospital
Who can join
Adults 18 to 90, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators aim to investigate the effect of the size of the base of the tumor in contact with the bladder mucosa on recurrence and progression in non-muscle invasive bladder tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06632340
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other Ankara Training and Research Hospital trials
Trials by the same sponsor.
- NCT07150455 — Evaluation of Myocardial Function by Global Longitudinal Strain (GLS) Measurement in 2D Echocardiography of Patients Wit · completed
- NCT07467421 — "Effectiveness of Physical Therapy Added to Transforaminal Injection in Lumbar Radicular Pain" · NA · completed
- NCT07143084 — Investigation of the Relationship Between Nutritional Status Assessment and Frailty in Critical Care Patients · enrolling by invitation
- NCT07310667 — Assessing the Relationship Between Frailty and Skeletal Muscle Thickness in Critically Ill Patients · enrolling by invitation
- NCT06946030 — Pseudoexfoliation and Carpal Tunnel Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06632340 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara Training and Research Hospital
- Last refreshed: 16 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06632340.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing